What Preparations Are Needed Before Renewing Overseas Registration for POCT Products?

Before renewing overseas registration for POCT products, manufacturers must systematically evaluate the regulatory requirements of the target country, product classification, validity of technical documentation, operational status of the quality management system, local agent arrangements, and post-market surveillance records. First, confirm whether the product falls under medical device regulation, then determine the risk classification (e.g., GHWP member states classify as A/B/C/D) to identify the corresponding registration pathway (self-registration or change of certificate holder). Technical documentation should cover performance validation, risk management (ISO 14971), clinical evaluation (if applicable), and stability studies. Existing NMPA, CE, FDA, or other records can be reused but require localized adaptation (e.g., language and standards differences). The quality management system must comply with ISO 13485 or MDSAP, and include records of internal audits, management reviews, and complaint handling within the last three years. Labels and instructions for use must be updated with version numbers, warnings, and local language. The local agent or authorized representative must hold a valid authorization agreement, and the agent information must match the registration certificate. Post-market surveillance includes adverse event reporting, Periodic Safety Update Reports (PSUR), and change notifications. Common risks include product classification changes, expired technical documents, system lapses, and failure to renew agent agreements. Manufacturers should start preparations at least 12 months before certificate expiry, prioritize reuse of already-approved documentation, and fill gaps based on target market differences to avoid renewal failure due to incomplete files.

Applicable Scenarios and Core Issues

POCT product overseas registration renewal applies when the initial registration certificate is about to expire and extension of validity is needed. Core issues include whether the product still meets current regulatory requirements, whether technical files and evidence chains are complete, whether the quality system remains effective, and whether the local agent has been renewed. Manufacturers often face rejection due to overlooked classification changes, missed standard updates, or agent contract lapses. This article addresses the essential preparations, decision logic, and common errors to help manufacturers reduce correction risks.

Registration Decision Logic

Step 1: Determine if the product falls under medical device regulation in the target country. POCT products are typically classified as in vitro diagnostic medical devices (IVDs); verify whether they are covered under local IVD regulations (e.g., EU IVDR, ASEAN IVD classification).

Step 2: Confirm the risk classification. GHWP member states generally use A (low risk) to D (high risk) classification, corresponding to different registration pathways (e.g., self-declaration for Class A, review for Classes B/C/D).

Step 3: Assess reusability of existing documentation. Technical files with NMPA, CE, FDA, or MDSAP certificates can reduce redundant work but require localization: language translation, standards differences (e.g., EN vs. IEC safety standards), and supplementary clinical evidence (e.g., performance data for specific populations).

Step 4: Identify the applicant entity. Overseas registration is typically held by a local agent; verify that the agent authorization is valid and unchanged before renewal.

Step 5: Review post-market surveillance records. Adverse event reports, on-site inspection results, and complaint handling records must be complete; otherwise, renewal approval may be affected.

If product classification or standards change (e.g., new Continuous Glucose Monitoring (CGM) classification), reassess clinical risk and registration pathway. Refer to the latest regulatory lists of the target country (e.g., Singapore HSA, Saudi SFDA, Brazil ANVISA) to avoid preparing under outdated regulations.

Documents and Evidence

Renewal requires submission of the following core documents:

• Technical Documentation: Product description, design principle, performance indicators (precision, accuracy, linear range), and stability data (real-time aging and accelerated studies).
• Risk Management File: Based on the latest version of ISO 14971, including risk analysis, risk control, and residual risk evaluation.
• Clinical Evaluation Report: If applicable, provide clinical trial summaries, literature reviews, or comparative studies; ensure clinical evidence covers the target population.
• Quality Management System Certificate: ISO 13485 (or MDSAP) valid, including internal audit and management review reports for the last three years, along with nonconformity handling records.
• Labels and Instructions for Use: Include product name, model, intended use, storage conditions, expiry date, warnings, and local language version; version numbers must match submitted files.
• Local Agent Authorization Letter: Clearly define agent responsibilities, agreement validity, termination clauses, and bear official seals of both parties.
• Post-Market Surveillance Data: Adverse event reports (PMS/PMCF), PSUR, and change management records.
• Copy of Original Registration Certificate: Ensure product information (name, classification, validity) matches the current application.

If standards cited in technical files have been updated (e.g., ISO 13485:2016 upgraded to 202X version), provide a gap analysis or declaration of conformity to the new standard. Performance validation data should cover prevalent subtypes or interfering substances in the target market; avoid using single-source samples only.

Common Errors

• Failure to verify product classification changes in advance: For example, some GHWP member states upgrade certain POCT products from Class B to Class C, but manufacturers still prepare as Class B, leading to missing evidence (e.g., insufficient clinical data).
• Outdated technical documentation versions: Using old risk management reports or performance evaluations from initial registration without reflecting new standards (e.g., ISO 20916 clinical study guidance) or post-market changes (e.g., software upgrades, reagent formulation adjustments).
• Quality system lapses or incomplete records: Internal system overhauls causing ISO 13485 certificate expiration, or missing records of internal audits, management reviews, complaint handling, and corrective and preventive actions (CAPA) for the last three years.
• Unupdated labels and instructions for use: Product name, warnings, or storage conditions changed, but submitted labels are old versions; local translations not approved or ambiguous.
• Expired local agent authorization: Agent agreement expired, agent company changed or dissolved, but no new authorization signed; agent information on registration certificate inconsistent with current authorization.
• Missing post-market surveillance reports: Failure to submit ongoing PMCF reports or PSUR, especially for high-risk products (e.g., infection markers, HbA1c) where sales data and adverse event analysis are required.
• Insufficient clinical evidence: POCT product added new target populations (e.g., children, pregnant women) after initial registration but without supplemental clinical data; or original clinical evaluation based on foreign data while target country requires local clinical trials.
• Ignoring multi-country registration differences: Different renewal timelines for the same product across countries; manufacturer fails to coordinate preparation, causing missed renewal windows in some countries.

Manufacturer Preparation Checklist

• Confirm the renewal deadline for the target country and develop a reverse schedule of at least 12 months.
• Establish a cross-departmental team (regulatory, R&D, quality, production, sales) with clear responsibilities.
• Collect the product's initial registration certificate, change approvals, and all historical communication records.
• Update technical documentation: Re-review the risk management report to ensure it aligns with the latest standards and actual use environment.
• Review quality system: Check ISO 13485/MDSAP certificate validity, and supplement missing records (internal audits, management reviews, training, CAPA).
• Update labels and instructions for use: Synchronize the latest version, and engage professional agencies for local language translation and review.
• Confirm local agent: Sign a renewal agreement; ensure the agent maintains local business qualifications.
• Organize post-market surveillance data: Establish an adverse event database, draft PSUR reports, and summarize complaints and recalls.
• For multi-country registration plans, assess reusability of core files and prepare a list of country-specific differences (e.g., clinical data, technical parameters, language requirements) in advance.
• Prepare a budget for one-time corrections: include translation fees, agent fees, testing fees, clinical study costs, etc., and reserve funds for addressing review questions.

AIMEILI's Perspective

Manufacturers most often misjudge the impact of product classification and regulatory version changes. Many POCT products, after initial registration, see target countries update classification rules or adopt new standards (e.g., EU IVDR transition period classification adjustments). If companies still prepare under old assumptions, they are likely to be asked for supplementary files, extending the renewal timeline.

Early in the project, prioritize two tasks: first, review the product's globally obtained certificates and technical files to assess which documents can be directly used for renewal countries and which require localization; second, contact the local agent or consultant to confirm if the target regulatory body has special requirements (e.g., Brazil ANVISA requires localized risk management reports, Saudi SFDA requires Arabic labels).

Reusable documents include: ISO 14971 risk management files, ISO 13485 system certificates, basic performance evaluation data, and general clinical evidence (e.g., global multicenter studies). Items that must be localized are: label and instruction translations, clinical evaluations (for ethnic/geographic differences), stability data (if storage conditions differ), registration certificate formats, and local agent information.

Local agent management, certificate control, and change management are critical. Many manufacturers experience certificate suspension or even cancellation due to agent changes or failure to renew agent authorization promptly. It is recommended to include agent qualification review in annual compliance checks and sign a renewal agreement defining responsibilities and obligations at least six months before renewal. Additionally, maintain control of the certificate (e.g., request original scanned copies of the registration certificate from the agent and regularly verify registration information).

For multi-country registration, adopt a “core file library” plus “country-specific package” strategy: compile standard technical documents (e.g., performance reports, risk analysis) into English master versions, then extract differences for each country, such as supplemental clinical data (e.g., HIV testing requiring specific subtype validation in the Middle East), packaging size (e.g., Japan requiring miniaturized packaging), and language requirements (e.g., local official languages in Middle East and Latin America). This approach significantly reduces redundant work and correction risks, improving renewal efficiency.

Frequently Asked Questions

Do technical documents need to be completely rewritten for renewal?

No. As long as the original technical documents comply with current standards and have not changed, they can be submitted directly. However, post-market change records (e.g., process optimization, raw material replacement) and recent stability data must be supplemented. If original files cite withdrawn standards (e.g., ISO 14971:2012 upgraded to ISO 14971:2019), update the risk management report and attach a gap declaration. Manufacturers are advised to establish a lifecycle management system for technical documents, updating the master version after each change.

How to handle design changes during the renewal period?

Differentiate based on the nature of the change: if the change affects safety or effectiveness (e.g., detection principle change, new test parameter), it must be submitted as a new registration or major change and cannot be combined with renewal; if it is a non-critical change (e.g., packaging material, extended shelf life), a change description and validation data can be submitted with the renewal, but the regulatory authority must be notified in advance. Manufacturers are advised to freeze the product version at least 12 months before the renewal deadline to avoid delays affecting certificate continuity.

How to coordinate timelines for multi-country renewal?

Prioritize by certificate expiry date from earliest to latest. For similar countries, parallel submissions may be possible (e.g., ASEAN members among GHWP, GCC countries). Key coordination points include: 1) prepare English master files uniformly, outsource country-specific translations; 2) sign agent authorization documents separately to avoid cross-authorization disputes; 3) note different review cycles (e.g., Brazil 6–12 months, Singapore 3–6 months) and allocate buffer time; 4) consider using the same consultant or agent for coordination to reduce communication costs.

What impact does the local agent have on renewal?

Most countries require the registration certificate to be held by a local agent. If the agent's term expires without renewal, the manufacturer cannot apply for renewal independently. The agent must provide: business license, authorization agreement, proof of ongoing operation, and commitment to cooperate with review. If changing agents, the manufacturer must first complete the agent change process (which may require resubmission of some documents), then initiate renewal. It is recommended to evaluate agent service quality six months in advance to avoid certificate invalidation due to agent non-cooperation.